No correlation between chemotherapy dose and treatment outcome in advanced ovarian cancer

Autor: Pff Wijn, J.J. Keuning, FE van Dam, Cmpw Mandigers, Ham Broelmann

Publikováno v: European Journal of Cancer. 29:S134

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2af6f6b9187e63143fcbdc9e9da56fbc
https://doi.org/10.1016/0959-8049(93)91357-q

Open communication between patients and relatives about illness & death in advanced cancer-results of the eQuiPe Study.

Autor: Haaksman M; Department of Health, Medical and Neuropsychology, University of Leiden, Leiden, the Netherlands. n.raijmakers@iknl.nl.; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501, DB, Utrecht, the Netherlands. n.raijmakers@iknl.nl., Ham L; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501, DB, Utrecht, the Netherlands.; Netherlands Association for Palliative Care (PZNL), Utrecht, the Netherlands., Brom L; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501, DB, Utrecht, the Netherlands., Baars A; Department of Internal Medicine, Hospital Gelderse Vallei, Ede, the Netherlands., van Basten JP; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands., van den Borne BEEM; Department of Pulmonology, Catharina Hospital, Eindhoven, the Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, The Netherlands., de Jong WK; Department of Pulmonology, Hospital Gelderse Vallei, Ede, the Netherlands., van Laarhoven HWM; Department of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands., van Lindert ASR; Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands., Mandigers CMPW; Department of Medical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., van der Padt-Pruijsten A; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., van Zuylen LC; Department of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands., van Vliet LM; Department of Health, Medical and Neuropsychology, University of Leiden, Leiden, the Netherlands., Raijmakers NJH; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501, DB, Utrecht, the Netherlands.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Mar 06; Vol. 32 (4), pp. 214. Date of Electronic Publication: 2024 Mar 06.

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.

Autor: Knikman JE; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wilting TA; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lopez-Yurda M; Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Henricks LM; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands., Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Meulendijks D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Late Development Oncology, AstraZeneca, Cambridge, UK., Nieboer P; Department of Internal Medicine, Wilhelmina Hospital Assen, Assen, the Netherlands., Droogendijk HJ; Department of Internal Medicine, Bravis Hospital, Roosendaal, the Netherlands., Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Mandigers CMPW; Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Hospital, Deventer, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands., Valkenburg-van Iersel L; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands., Vulink A; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands., van der Poel MHW; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Baars A; Department of Internal Medicine, Hospital Gelderse Vallei, Ede, the Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Schellens JHM; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Cats A; Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 10; Vol. 41 (35), pp. 5411-5421. Date of Electronic Publication: 2023 Aug 28.

Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer.

Autor: Kroon LL; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501 DB, Utrecht, The Netherlands.; University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van Roij J; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501 DB, Utrecht, The Netherlands.; Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands.; Netherlands Association for Palliative Care (PZNL), Utrecht, The Netherlands.; Department of Psychology, Pantein, Boxmeer, The Netherlands., Korfage IJ; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands., Reyners AKL; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., van den Beuken-van Everdingen MHJ; Center of Expertise Palliative Care, Maastricht University Medical Center, Maastricht, The Netherlands., den Boer MO; Department of Medical Oncology, Laurentius Hospital, Roermond, The Netherlands., Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands., de Graeff A; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Hendiks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, The Netherlands., Hunting JCB; Department of Medical Oncology, St. Antonius Hospital, Utrecht, The Netherlands., de Jong WK; Department of Pulmonology, Hospital Gelderse Vallei, Ede, The Netherlands., Kuip EJM; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Laarhoven HWM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., van Leeuwen L; Department of Medical Oncology, Diakonessenhuis, Utrecht, The Netherlands., van Lindert ASR; Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands., Mandigers CMPW; Department of Medical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Nieboer P; Department of Medical Oncology, Wilhelmina Hospital Assen, Assen, The Netherlands., van der Padt-Pruijsten A; Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Sommeijer DW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, FlevoHospital, Almere, The Netherlands., Thijs MF; Department of Medical Oncology, Ikazia Hospital, Rotterdam, The Netherlands., Tiemessen MA; Department of Pulmonology, Dijklander Hospital, Hoorn, The Netherlands., Vos AH; Department of Medical Oncology, Bernhoven Hospital, Uden, The Netherlands., Vreugdenhil A; Department of Medical Oncology, Maxima Medical Center, Eindhoven, The Netherlands., Werner PT; Department of Medical Oncology, VieCuri Medical Center, Venlo, The Netherlands., van Zuylen L; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., van de Poll-Franse LV; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501 DB, Utrecht, The Netherlands.; Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands.; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Raijmakers NJH; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), PO box 19079, 3501 DB, Utrecht, The Netherlands. n.raijmakers@iknl.nl.; Netherlands Association for Palliative Care (PZNL), Utrecht, The Netherlands. n.raijmakers@iknl.nl.

Publikováno v: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2021 Jun; Vol. 15 (3), pp. 380-385. Date of Electronic Publication: 2021 Apr 10.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Autor: Henricks LM; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: l.henricks@nki.nl., Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Meulendijks D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, the Netherlands., Frederix GWJ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Kienhuis E; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Creemers GJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Baars A; Department of Internal Medicine, Hospital Gelderse Vallei, Ede, the Netherlands., Dezentjé VO; Department of Internal Medicine, Reinier de Graaf Hospital, Delft, the Netherlands; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Imholz ALT; Department of Internal Medicine, Deventer Hospital, Deventer, the Netherlands., Jeurissen FJF; Department of Internal Medicine, Haaglanden Medical Center, The Hague, the Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Haga Hospital, The Hague, the Netherlands., Jansen RLH; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Droogendijk HJ; Department of Internal Medicine, Bravis Hospital, Roosendaal, the Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Nieboer P; Department of Internal Medicine, Wilhelmina Hospital Assen, Assen, the Netherlands., van de Poel MHW; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Mandigers CMPW; Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Kuilenburg ABP; Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, Amsterdam, the Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Cats A; Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Schellens JHM; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Jan; Vol. 107, pp. 60-67. Date of Electronic Publication: 2018 Dec 11.